Valuation: Pacific Biosciences of California, Inc.

Market Cap 395M 339M 316M 290M 546M 37.73B 555M 3.73B 1.46B 18.92B 1.48B 1.45B 62.57B P/E 2026 *
-2.89x
P/E 2027 * -2.74x
Enterprise Value 395M 339M 316M 290M 546M 37.73B 555M 3.73B 1.46B 18.92B 1.48B 1.45B 62.57B EV / Sales 2026 *
2.49x
EV / Sales 2027 * 2.15x
Free-Float
91.08%
Yield 2026 *
-
Yield 2027 * -
1 day-3.84%
1 week+2.97%
Current month-24.05%
1 month-23.32%
3 months-1.06%
6 months-32.10%
Current year-37.15%
1 week 0.96
Extreme 0.9554
1.02
1 month 0.93
Extreme 0.9278
1.26
Current year 0.93
Extreme 0.9278
2.21
1 year 0.93
Extreme 0.9278
2.3
3 years 0.78
Extreme 0.78
10.9
5 years 0.78
Extreme 0.78
26.47
10 years 0.78
Extreme 0.78
45.8
Manager TitleAgeSince
Chief Executive Officer 53 2026-08-04
Director of Finance/CFO 57 2025-03-30
Chief Tech/Sci/R&D Officer - 2012-06-30
Director TitleAgeSince
Director/Board Member 67 2003-12-31
Director/Board Member 72 2008-12-31
Director/Board Member 69 2012-01-17
Change 5-day change 1-year change 3-year change Capi.($)
-3.84%+2.97% - - 395M
+4.16%+1.75%+23.13%+15.24% 227B
+5.97%+2.77%-0.33%-15.87% 149B
+1.67%-0.88%-17.00%+39.09% 141B
+3.05%+1.15%-49.87%+3.63% 75.37B
+1.43%-0.83%+16.91%+20.50% 53.19B
+1.32%+2.43%-16.15%-12.15% 51.88B
+4.70%+4.84%+29.39%+30.32% 43.89B
+3.64%-0.07%+39.67%+54.01% 40.86B
+2.74%+3.24%+0.88%+9.16% 33.7B
Average +2.13%+1.37%+2.96%+15.99% 90.55B
Weighted average by Cap. +3.25%+1.31%+2.52%+13.71%

Financials

2026 *2027 *
Net sales 158M 136M 127M 116M 219M 15.12B 222M 1.5B 586M 7.58B 594M 581M 25.08B 184M 158M 147M 135M 254M 17.59B 258M 1.74B 681M 8.82B 691M 676M 29.17B
Net income -137M -118M -110M -101M -189M -13.1B -193M -1.3B -507M -6.57B -515M -504M -21.73B -148M -127M -118M -109M -204M -14.14B -208M -1.4B -547M -7.09B -555M -543M -23.44B
Net Debt - -
Logo Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Employees
485
Date Price Change Volume
26-08-19 €0.9554 -3.84% 0
26-08-18 €0.9936 +0.06% 0
26-08-17 €0.9930 +1.58% 0
26-08-14 €0.9776 +0.60% 48
26-08-13 €0.9718 +4.74% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.270USD
Average target price
2.292USD
Spread / Average Target
+80.45%

Quarterly revenue - Rate of surprise